Evidence map›Paper›PMID 39119928›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

Histones Methyltransferase NSD3 Inhibits Lung Adenocarcinoma Glycolysis Through Interacting with PPP1CB to Decrease STAT3 Signaling Pathway.

Yanling Zhou, Xintong Peng, Cheng Fang, Xin Peng, Jianing Tang, Zuli Wang, Yao Long, Jielin Chen, Yuanhao Peng, Zewen Zhang and 7 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Psoralen and Isopsoralen fromPharmaceuticals (Basel, Switzerland) · 2026
    Article
  3. The role ofFrontiers in medicine · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yanling ZhouDepartment of Oncology, Institute of Medical Sciences, National Clinical Research Center for Geriatric Disorders, Institue of Medical Sciences, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Xintong PengKey Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Cheng FangDepartment of Cardiac Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Xin PengDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Jianing TangDepartment of Liver Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Zuli WangCenter for Tissue Engineering and Stem Cell Research, Guizhou Medical University, Guiyang, Guizhou, 561113, China.
Yao LongKey Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Jielin ChenDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Yuanhao PengKey Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Zewen ZhangKey Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Yanmin ZhouDepartment of Oncology, Institute of Medical Sciences, National Clinical Research Center for Geriatric Disorders, Institue of Medical Sciences, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Jun TangKey Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Jingzhong LiaoDepartment of Laboratory Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Desheng XiaoDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Yongguang TaoKey Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.ORCID 0000-0003-2354-5321
Ying ShiKey Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Shuang LiuDepartment of Oncology, Institute of Medical Sciences, National Clinical Research Center for Geriatric Disorders, Institue of Medical Sciences, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.

Funding

National Natural Science Foundation of China 81872285National Natural Science Foundation of China 82072594:82073097:81874139:82073136:81772927:82203160National Natural Science Foundation of China 82372598the Natural Science Foundation of Hunan Province 2021JJ30907the Natural Science Foundation of Hunan Province 2024JJ3048the Natural Science Foundation of Hunan Province 2024JJ6683
6 · The paper itself

Abstract

Histones methyltransferase NSD3 targeting H3K36 is frequently disordered and mutant in various cancers, while the function of NSD3 during cancer initiation and progression remains unclear. In this study, it is proved that downregulated level of NSD3 is linked to clinical features and poor survival in lung adenocarcinoma. In vivo, NSD3 inhibited the proliferation, immigration, and invasion ability of lung adenocarcinoma. Meanwhile, NSD3 suppressed glycolysis by inhibiting HK2 translation, transcription, glucose uptake, and lactate production in lung adenocarcinoma. Mechanistically, as an intermediary, NSD3 binds to PPP1CB and p-STAT3 in protein levels, thus forming a trimer to dephosphorylate the level of p-STAT3 by PPP1CB, leading to the suppression of HK2 transcription. Interestingly, the phosphorylation function of PPP1CB is related to the concentration of carbon dioxide and pH value in the culture environment. Together, this study revealed the critical non-epigenetic role of NSD3 in the regulation of STAT3-dependent glycolysis, providing a piece of compelling evidence for targeting the NSD3/PPP1CB/p-STAT3 in lung adenocarcinoma.

Indexed as

Adenocarcinoma of LungGlycolysisHistone-Lysine N-MethyltransferaseLung NeoplasmsSignal TransductionSTAT3 Transcription FactorAnimalsCell Line, TumorCell ProliferationDisease Models, AnimalFemaleHumansMaleMiceMice, NudeNuclear ProteinsHistone-Lysine N-MethyltransferaseNSD3 protein, humanNuclear ProteinsPPP1CB protein, humanProtein Phosphatase 1STAT3 protein, humanSTAT3 Transcription Factorglycolysishistones methyltransferaselung adenocarcinomaSTAT3 signaling pathway

Identifiers

PMID39119928
PMCPMC11481231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.